Recombinant and microbial P450 and glycosylating technology have been developed for accessing metabolites at mg to 100s grams scale, the company said.
These enzymes, which resemble human systems, are a powerful tool for accessing metabolites efficiently in one step from the parent API.
The application of biocatalysis is expected to result in reduced energy costs, lowered impact on the environment and efficient multi-tonne processing in timelines comparable to traditional chemistry.
Biocatalysis head Tom Moody said that Biocatalysis is now Almac’s first choice for any scale-up chemistry involving chirality resulting in cheaper, cleaner and robust processes.